Impact of combination medical therapy on mortality in patients with acute coronary syndromes;Impacto da combinação de terapêutica farmacológica na mortalidade em doentes com síndrome coronária aguda

Revista Portuguesa de Cardiologia

Volumn 25, Issue 12, 2006, Pages 1109-1118

  Timóteo, Ana Teresa ^a,b   Fiarresga, António ^a   Feliciano, Joana ^a   Pelicano, Nuno ^a   Ferreira, Lurdes ^a   Oliveira, José Alberto ^a   Serra, José ^a   Ferreira, Rui ^b   Quininha, Jorge ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

^b Edifício C 9A ^*  (Portugal)

Author keywords

Acute coronary syndrome; Drugs; Prognosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; ST SEGMENT ELEVATION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME;

EID: 33847009417     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Braunwald E, Antman EM, Beasly JW, et al. ACC /AHA guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. J Am Coll Cardiol 2002; 40: 1366-1374.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC / AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC / AHA Task Force on Practice Guidelines (Committee to revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44: 671-719.
3. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840.
4. Van de Werf F, Ardissimo D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.
5. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J 2002; 23: 1190-1201.
6. Scandinavian Simvastatin Survival Study Group: randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-1389.
7. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Study Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
8. The Long-term Intervention with Pravastatin in Ischaemic Disease Study group: Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
9. MRC / BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controUed trial. Lancet 2002; 360: 7-22.
10. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study. A randomised controlled trial. JAMA 2001; 285: 1711-1718.
11. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT - LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158.
12. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86.
13. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
15. The Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
17. Mukherjee D, Fang J, Chetcuti S, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-9.
18. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Performance Measures (ST-elevation and non-ST-Elevation Myocardial Infarction Performance Measures Writing Committee). Circulation. 2006; 113: 732-61.
19. Mosarcci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation. 2006; 113: 814-22.